Firm Represents Barr in Merger with Teva
07.21.08
This is only gets display when printing
Simpson Thacher is representing Barr Pharmaceuticals, Inc. in connection with its announced acquisition by Teva Pharmaceutical Industries Inc., for total consideration of approximately $7.46 billion, plus the assumption of net debt of Barr of approximately $1.5 billion. Teva is the world’s largest generic drug company and Barr is the fourth largest generic drugmaker. The acquisition is subject to approval by the stockholders of Barr and various antitrust approvals.
The Simpson Thacher team advising Barr on the transaction includes: Gary Horowitz, Doug Bacon, Nomaan Raja, William Freiberg, Sean Murphy, Adam Booken and summer associates Matt Levy and Chad Pearlman (M&A); Wonda Joseph and summer associate Jennifer Peppin (Benefits); Gary Mandel, Noah Beck and Jason Vollbracht (Tax); David Vann and Ketan Jhaveri (Competition); Adeeb Fadil (Environmental); Jacqueline Rosenblum (Labor); Noah Leibowitz and Marcela Robledo (IP); and paralegal Natalie Kone.